Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant
- Conditions
- Cardiomyopathy
- Registration Number
- NCT00456040
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation.
- Detailed Description
Systemic amyloidosis is a progressive disease leading to organ failure and death. Treatment has improved survival with stem-cell transplantation. Unfortunately, patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation.
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased.
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis, if chemotherapy and stem-cell transplantation is performed after a heart transplant.
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
- Patients with amyloidosis
- NYHA class III or IV heart failure
- Patients undergoing heart transplant evaluation
- Patients less than 18 years of age
- Patients who have unstable pulse and blood pressure
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method